Literature DB >> 22739143

Gene, stem cell, and future therapies for orphan diseases.

M Ian Phillips1.   

Abstract

There are an estimated 7,000 "orphan diseases," but treatments are currently available for only about 5% of them. Recent progress in the advanced platforms of gene therapy, stem cell therapy, gene modification, and gene correction offers possibilities for new therapies and cures for rare diseases. Many rare diseases are genetic in origin, and gene therapy is being successfully applied to treat them. Human stem cell therapy, apart from bone marrow transplants, is still experimental. Genetic modification of stem cells can make stem cell-based products more effective. Autologous induced pluripotent stem (iPS) cells, when combined with new classes of artificial nucleases, have great potential in the ex vivo repair of specific mutated DNA sequences (zinc-finger proteins and transactivator-like effector nucleases). Patient-specific iPS cells can be corrected and transplanted back into the patient. Stem cells secrete paracrine factors that could become new therapeutic tools in the treatment of orphan diseases. Gene therapy and stem cell therapy with DNA repair are promising approaches to the treatment of rare, intractable diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22739143     DOI: 10.1038/clpt.2012.82

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Necessity of cooperation with government on publication of scientific research results for intractable diseases.

Authors:  Yoshinori Inagaki; Peipei Song
Journal:  Intractable Rare Dis Res       Date:  2013-05

Review 2.  Dawn of ocular gene therapy: implications for molecular diagnosis in retinal disease.

Authors:  Jacques Zaneveld; Feng Wang; Xia Wang; Rui Chen
Journal:  Sci China Life Sci       Date:  2013-02-08       Impact factor: 6.038

3.  Tumor-free iPS stem cells for heart cells.

Authors:  M Ian Phillips
Journal:  Cell Cycle       Date:  2014-04-22       Impact factor: 4.534

4.  EENdb: a database and knowledge base of ZFNs and TALENs for endonuclease engineering.

Authors:  An Xiao; Yingdan Wu; Zhipeng Yang; Yingying Hu; Weiye Wang; Yutian Zhang; Lei Kong; Ge Gao; Zuoyan Zhu; Shuo Lin; Bo Zhang
Journal:  Nucleic Acids Res       Date:  2012-11-29       Impact factor: 16.971

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.